Tag - SRRA

Developments

Three finalists announced for Bloom Burton Award

The finalists for the 2023 Bloom Burton Award are: Stephen Dilly, former president and CEO, Sierra Oncology Ian Mortimer, president and CEO, Xenon Pharmaceuticals Dave Wessinger, co-founder and CEO, and Mike Wessinger...

May 4, 2023

Markets

HCW starts Sierra Oncology at buy; PT $20

H.C. Wainwright launched coverage of Sierra Oncology (NASDAQ:SRRA) with a “buy” rating and $20 price target. The stock closed at $12.46 on July 29. Sierra Oncology is in the midst of a Phase 3 MOMENTUM study with its...

July 30, 2020

Developments

Sierra Oncology acquires momelotinib from Gilead

Sierra Oncology (NASDAQ:SRRA) has acquired the drug candidate, momelotinib, from Gilead Sciences (NASDAQ:GILD) for a $3-million upfront fee and potential milestone payments of up to $195-million, which are largely...

August 22, 2018

Tag - SRRA

Three finalists announced for Bloom Burton Award

HCW starts Sierra Oncology at buy; PT $20

Sierra Oncology acquires momelotinib from Gilead

General

More